PHA & Polyhydroxy Acids: Gluconolactone vs Lactobionic Acid for Sensitive Skin

Overview #

pH is not the only reason PHAs outperform AHAs on reactive skin. The molecular weight difference is the real mechanism — and most brands briefing us on “gentle exfoliation” don’t fully appreciate what that means at the formulation level. Gluconolactone and lactobionic acid sit in the same PHA family, but they behave differently enough in our stability chambers and in clinical data that we treat them as distinct actives, not interchangeable options. If you’re building a sensitive-skin exfoliation line and you haven’t decided between these two yet, this is where we’d start the conversation.

The Mechanism Gap Between PHAs and AHAs — Why It Actually Matters #

The standard explanation is that PHAs have larger molecules, so they penetrate more slowly and cause less irritation. That’s true, but it undersells the story. Gluconolactone (MW ~178 Da) and lactobionic acid (MW ~358 Da) both carry multiple hydroxyl groups that interact with the stratum corneum differently than glycolic acid (MW ~76 Da) does. At equivalent pH — say, 3.8 — glycolic acid drives measurable TEWL increases within 48 hours of repeated application. In our internal patch testing, gluconolactone at the same pH produced no statistically detectable TEWL change over the same window.

Lactobionic acid goes further. The disaccharide backbone gives it genuine humectant activity alongside the exfoliation function. We’ve measured water uptake in formulations containing 8% lactobionic acid that rivals 2% sodium hyaluronate in short-term occlusion tests. That’s not a marketing claim — it’s something we see consistently in our lab when we run comparative moisture sorption assays.

The practical implication: gluconolactone is your workhorse for pH-driven exfoliation with a clean tolerability profile. Lactobionic acid is what you reach for when the brief says “exfoliation plus barrier support” — rosacea-adjacent skin, post-procedure recovery, or any consumer who’s already sensitized.

Drop below pH 3.5 with either of these and you’re in regulatory grey territory in the EU. Most brands don’t realize this until we tell them.

Clinical Evidence: What the Data Actually Shows #

This is where we need to be honest about the evidence base. PHA clinical literature is thinner than AHA literature, and some of the most-cited studies are industry-funded with small sample sizes. We use the data, but we flag the limitations to brand partners before they build claims around it.

Gluconolactone — Tolerability vs. Glycolic Acid

The head-to-head data is actually pretty clear here. A double-blind, split-face RCT (n=20, 12 weeks) comparing 8% gluconolactone lotion against 8% glycolic acid lotion in subjects with self-reported sensitive skin showed equivalent keratolytic efficacy — both groups achieved measurable reduction in corneometer-assessed surface roughness — but the gluconolactone arm reported 68% fewer stinging events at week 4. What that study doesn’t tell you, and what we’ve learned from our own batches, is the stability story. Gluconolactone hydrolyzes to gluconic acid in aqueous systems above pH 4.5, which shifts your active concentration over shelf life. We now formulate gluconolactone-containing products at pH 3.8–4.2 and run 40°C/75% RH stability for a minimum of 12 weeks before releasing any formula.

Lactobionic Acid — Barrier Function and Antioxidant Activity

A published open-label study (n=33, 8 weeks) evaluated 8% lactobionic acid cream in subjects with atopic dermatitis-prone skin. The primary endpoint was TEWL reduction; secondary endpoints included ITA° (skin tone evenness) and self-assessed dryness. Results: TEWL decreased by 22% from baseline, ITA° improved by 14%, and 79% of subjects reported reduced dryness sensation by week 4. The study design wasn’t blinded, which limits how hard you can push the claims — but the TEWL data is consistent with what we see in our own in-house occlusion testing.

Lactobionic acid also chelates metal ions, which gives it a secondary antioxidant function. We’ve used this in formulations where we’re trying to protect other actives — vitamin C combinations, for instance — and the chelation effect measurably extends ascorbic acid stability in our accelerated tests. See our Vitamin C & Antioxidant Systems technical notes for how we handle that combination.

Glucono-delta-lactone (GdL) as a pH Modulator

This one gets overlooked. GdL isn’t just a PHA precursor — it’s a slow-release acidifier we use to drive pH down gradually during manufacturing without the sharp drop you get from adding lactic or citric acid directly. In emulsion systems, we’ve used GdL at 0.5–1.5% to achieve a final pH of 4.0–4.5 with better batch-to-batch consistency than direct acid addition. The clinical evidence for GdL as a standalone exfoliant is weaker than for gluconolactone or lactobionic acid, but its formulation utility is real and underappreciated.

Evidence Strength Comparison #

Mandelic acid sits in a grey zone — some suppliers classify it as a PHA, others don’t. We include it here because brand partners frequently ask about it in the same brief, and the tolerability profile in Fitzpatrick IV–VI skin is genuinely better than glycolic at equivalent concentrations. For more on how we approach exfoliation actives across skin tone ranges, see our Acid Exfoliation Technology documentation.

Where Most Brands Get This Wrong #

Honestly, the most common mistake we see is treating PHA concentration as the primary efficacy lever. It isn’t. pH is. A 10% gluconolactone formula at pH 5.5 will underperform a 5% formula at pH 3.8 on every keratolytic endpoint we measure. Brands come to us with “we want 10% PHA” on the brief, and the first thing we ask is: what pH are you targeting, and what’s your preservative system?

That second question matters more than most people expect. At pH 3.8–4.2, your preservative options narrow significantly. Phenoxyethanol performs well in this range. Parabens are fine. But if a brand is positioning as “paraben-free and preservative-free” — which we see constantly in the clean beauty space — you’re left with organic acid systems that are already partially consumed by the low pH environment. We’ve had batches pass initial challenge testing and then fail at week 8 of PCT when gram-negative organisms appeared. That was a 200kg production batch. We caught it before release, but it cost the client a full reformulation cycle.

The clean beauty positioning pressure is real, and we understand it commercially. But a lot of clean beauty brands underestimate how fragile low-pH preservative systems become at production scale. This is usually where projects go sideways.

There’s also a cost dimension that doesn’t come up enough. Lactobionic acid costs roughly 4–6× more per kilogram than gluconolactone at the grades we source for cosmetic use. At 8% loading in a 30ml serum, that difference is meaningful at MOQ 3,000 units — we’re talking a $0.35–$0.55 per-unit COGS impact before packaging. For an indie brand pricing at $45 retail, that’s manageable. At $28 retail, it changes the margin conversation entirely.

Regulatory Claim Substantiation: EU, US, and NMPA #

This is where the clinical evidence review becomes commercially relevant. Having the data is one thing. Knowing what claims it supports — and in which market — is another.

EU Market

Under EU Cosmetics Regulation 1223/2009, cosmetic claims must be substantiated by evidence, but the regulation doesn’t prescribe what type of evidence is required. In practice, the SCCS Scientific Opinion framework and the Common Criteria Regulation (EU 655/2013) set the bar. For a claim like “clinically shown to reduce visible skin roughness,” you need a study that is methodologically sound, conducted on the finished product (not the raw material), and with a sample size that supports statistical significance. The n=20 gluconolactone RCT we cited above is borderline — we’d want to supplement it with an in-house consumer perception study at minimum n=50 before advising a brand to use “clinically proven” language in the EU.

AHA/PHA concentration and pH also intersect with the EU’s AHA guidance, which recommends maximum 10% AHA at pH ≥3.5 for rinse-off products and flags leave-on products above certain concentrations for additional safety assessment. PHAs aren’t explicitly named in the same guidance, but we advise clients to apply the same pH floor conservatively.

US Market

The FDA Cosmetics Guidelines framework is more permissive on claim substantiation — there’s no mandatory pre-market approval for cosmetic claims, but the FTC’s “competent and reliable scientific evidence” standard applies to any efficacy claim. For PHA products, this means you can support “exfoliates to reveal smoother skin” with consumer perception data alone. “Clinically tested” requires an actual clinical study. “Dermatologist tested” requires documented dermatologist involvement — we can facilitate this through our network, but it adds 8–12 weeks to the development timeline.

One thing we flag for US-bound products: if your PHA formula contains salicylic acid as a co-active (common in acne-adjacent positioning), you’re in OTC drug territory under FDA rules. That changes everything — testing requirements, labeling, manufacturing standards. We’ve had brands come to us with “BHA + PHA exfoliant” briefs not realizing the salicylic acid component triggers drug classification.

NMPA (China)

NMPA Cosmetic Regulation requires that any efficacy claim be supported by testing conducted according to NMPA-recognized methods, and since the 2021 Cosmetic Supervision and Administration Regulation (CSAR) came into force, the requirements have tightened considerably. For exfoliation claims, human efficacy testing using NMPA-accepted protocols is expected. The good news: our facility is set up to run NMPA-compliant efficacy testing in-house, which shortens the timeline compared to outsourcing to a third-party CRO. The less good news: the NMPA registration process for new raw materials — including some novel PHA derivatives — can add 6–18 months to launch timelines if the ingredient isn’t already on the approved list.

For brands targeting all three markets simultaneously, we almost always recommend building the claim architecture around the most restrictive market first (typically EU or NMPA, depending on the claim type), then adapting down for the US. It’s not a perfect solution. But it’s less painful than building three separate claim packages from scratch.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a PHA brief lands on our desk — because the answers determine pH target, preservative system, and which clinical data we need to generate or license.

If you’re targeting EU sensitive-skin positioning with a “clinically tested” claim, budget for a finished-product study. Raw material supplier data won’t get you there. We typically recommend 8% gluconolactone at pH 4.0–4.2 as the starting point — it’s the best-evidenced concentration range, it’s manufacturable at scale without exotic equipment, and it sits comfortably within EU AHA guidance pH floors.

If the brief is “exfoliation plus barrier repair” — which we see a lot in the post-procedure and rosacea-adjacent space — lactobionic acid at 5–8% is where we’d go, probably in a cream or lotion base rather than a water-thin serum. The humectant activity changes the texture profile in ways consumers notice.

One thing we push back on regularly: stacking multiple exfoliation actives in the same formula to hit a higher “total acid percentage” on pack. We’ve seen briefs with gluconolactone + lactic acid + mandelic acid + salicylic acid all in one product. The stability interactions are complex, the pH management is difficult, and in the US, that salicylic acid inclusion may trigger OTC classification. Simpler is usually better here. Pick one primary active, support it with the right pH and preservative system, and build the clinical story around that.

Packaging matters more than most brands expect for this category. Airless pump or laminate tube is strongly preferred — repeated air exposure at low pH accelerates oxidation of some PHA derivatives. Standard open-mouth jar is a stability risk we’ll flag in every project review.

Frequently Asked Questions #

Q: We want to call it “8% PHA” on pack — does the clinical data actually support that concentration?

For gluconolactone, yes — the tolerability and efficacy data we cited is specifically at 8%, so the concentration claim is directly supported. For lactobionic acid, the TEWL study was also at 8%, so you’re on solid ground there too. Just make sure your finished-product pH matches the study conditions (3.8–4.5 range) or you’re not really replicating the evidence.

Q: Can we combine gluconolactone and lactobionic acid in the same formula?

We do this regularly. A typical split is 5% gluconolactone + 3% lactobionic acid, which keeps total PHA load at 8% while giving you the barrier-support story from the lactobionic acid. Stability is manageable at pH 4.0–4.2. The COGS impact is real — expect roughly $0.25–$0.40 per unit more than a single-active formula at equivalent total concentration.

Q: Our brand is “clean” — can we avoid phenoxyethanol in a low-pH PHA formula?

Honestly, this is a tough one. Below pH 4.5, your effective preservative options narrow. Organic acid systems (levulinic acid, anisic acid combinations) can work, but we’ve seen them fail PCT at production scale in ways they don’t at lab scale. If you’re committed to phenoxyethanol-free, we’d want to run extended challenge testing — minimum 26 weeks — before we’d feel comfortable releasing. Budget for that timeline.

Q: Does NMPA require separate registration for gluconolactone and lactobionic acid?

Both are on the NMPA’s existing cosmetic ingredient inventory, so no new raw material registration is required for standard use. What you do need is NMPA-compliant efficacy testing for any on-pack efficacy claims under the 2021 CSAR framework. That testing typically takes 10–14 weeks through our in-house process.

Q: We’ve seen “polyhydroxy acid” used to describe mandelic acid — is that accurate, and does it affect our claims?

Mandelic acid classification is genuinely inconsistent across suppliers and markets. Its MW (~152 Da) is higher than glycolic but lower than gluconolactone, and it doesn’t carry the multiple hydroxyl groups that define classical PHAs. We’d be cautious about calling it a PHA on pack in the EU — if a responsible authority challenged the classification, you’d need to defend it. In the US, the FTC standard is looser, but we still recommend “alpha hydroxy acid” or just “mandelic acid” to avoid any substantiation gap.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.